Titin (TTN): from molecule to modifications, mechanics, and medical significance

Authors, Journal, Affiliations, Type, DOI

• Christine M. Loescher, Anastasia J. Hobbach, Wolfgang A. Linke
• Cardiovascular Research (2022) 118:2903–2918
• Department of Cardiology I, University Hospital Münster, Germany
• Invited review article
• DOI: https://doi.org/10.1093/cvr/cvab328

Overview

This invited review from the Linke laboratory provides a comprehensive account of titin's molecular biology, covering structure, isoform diversity, three classes of post-translational modifications (PTMs), protein quality control (PQC), and how dysregulation at each level contributes to heart failure. A central focus is the newly clarified pathomechanisms of TTN-truncation cardiomyopathy (TTNtv-DCM) — titin haploinsufficiency combined with truncated protein toxicity and PQC deregulation — with implications for therapeutic targeting. Multiple therapeutic strategies aimed at correcting titin stiffness or PQC are reviewed, though most clinical trials (RELAX, VITALITY, SOCRATES) have failed to replicate pre-clinical benefits in human HFpEF.

Keywords

Heart failure, Cardiomyopathy, Sarcomere, Mechanical function, Signalling

Key Takeaways

1. Titin Structure and Isoform Diversity

• Titin spans the half-sarcomere from Z-disc to M-band as the third sarcomeric filament (alongside myosin and actin). A-band titin is inextensible; I-band titin is elastic; M-band titin serves structural/regulatory functions.
• The I-band spring contains three extensible elements: PEVK repeats (proline-glutamic acid-valine-lysine), Ig domains, and the N2B-unique sequence (N2Bus).
• Human TTN has 364 exons (363 in the meta-transcript). Principal cardiac isoforms: N2B (3 MDa, stiff, short spring), N2BA (3.2–3.8 MDa, compliant, long spring), Novex-3 (~650 kDa), and Cronos (2.3 MDa; internal promoter, more expressed in developing than adult CMs).
• Healthy adult left ventricle: N2BA:N2B ratio ~30:70 to 40:60. This ratio is relatively stable during normal ageing.
• The N2BA:N2B isoform switch is regulated by splicing factor RBM20, which suppresses I-band exon inclusion. RBM20 pathogenic variants → oversized N2BA isoforms, greater titin compliance, DCM.
• Isoform switch in HF: Increased N2BA proportion (relative to N2B) in HFrEF, HFpEF, and aortic stenosis → lower titin stiffness, greater end-diastolic volume. However, some studies in aortic stenosis and HFpEF report opposite or no change — may depend on disease stage, chamber, and species differences.
• Titin spring stiffness sets length-dependent activation (LDA), the basis of the Frank-Starling law. Stiffer (N2B-enriched) springs → greater LDA; compliant (N2BA-enriched) springs → blunted LDA → reduced cardiac output in HF.

2. Post-Translational Modifications (PTMs)

2a. Acetylation

• Acetylation sites detected along the entire titin molecule by mass spectrometry (rat heart).
• Proposed mechanism: increased acetylation in HFpEF (due to reduced SIRT1 deacetylase activity) adds negative charges to positively charged regions → intramolecular interactions → increased titin stiffness.
• NAD⁺/NAM (nicotinamide) restores SIRT1 activity → deacetylation of titin → decreased stiffness in HFpEF animal models. No clinical trials yet; conflicting results with HDAC inhibitors in similar models.

2b. Oxidation

• Titin is a primary target of oxidative stress. Oxidation at I-band "hotspots" (N2Bus, distal Ig domains) modulates stiffness.
• UnDOx (unfolded domain oxidation): Cryptic cysteines exposed by Ig domain unfolding become oxidized. Two competing outcomes:
  • S-glutathionylation → domain cannot refold → increased contour length → decreased titin stiffness (compliance)
  • Disulphide bonding (in Ig domains or N2Bus) → prevents full extension → increased titin stiffness
• Under cardiac stress (increased preload/afterload): low-level oxidation acts as a physiological stiffness modulator. In ischaemia or HFpEF metabolic syndrome: oxidation becomes extensive and pathological.
• Reversible with reductants (dithiothreitol, glutathione) in vitro.

2c. Phosphorylation

• Over 300 phosphorylation sites identified in titin. Most studied regions: N2Bus and PEVK.
• Opposing effects:
  • N2Bus phosphorylation (PKA, PKG, PKD, ERK2, CaMKIIδ) → decreased titin stiffness (electrostatic repulsion within net-negative N2Bus → improved extensibility)
  • PEVK phosphorylation (PKCα, CaMKIIδ, PKD) → increased titin stiffness (increased intramolecular interactions in net-positive PEVK region)
• Key phosphosites in N2Bus: S4010, S4062, S4099, S4185 (human UniProtKB #Q8WZ42-1)
• Key PEVK phosphosites: S11878, S12022
• In HF: N2Bus hypo-phosphorylation + PEVK hyper-phosphorylation → increased cardiomyocyte passive stiffness — a consistent finding across multiple HF phenotypes.
• cGMP-PKG pathway as therapeutic target:
  • PDE5A inhibitor (sildenafil): boosted titin phosphorylation and reduced LV stiffness in dog models → RELAX trial in HFpEF: no significant improvement in diastolic function.
  • sGC stimulators: improved titin N2Bus phosphorylation in animal models → VITALITY and SOCRATES clinical trials: no improvement in HFpEF.
  • Explanation for failures: dosage/metabolic differences, pathway compartmentalization, complexity of cGMP-PKG intermediate steps.
• Metformin + insulin and neuregulin-1 improved titin phosphorylation and diastolic function in diabetic HFpEF models (pre-clinical only).

3. Protein Quality Control (PQC)

• Titin turnover: ~3 days in cell culture; 2–3 weeks in adult mouse hearts. Maintenance involves chaperones → protease pre-digestion → UPS and autophagy-lysosomal degradation.
• Chaperones: sHSPs (αB-crystallin/HSPB5, HSP27/HSPB1) translocate from cytosol/Z-disc to N2Bus, N2A, and proximal Ig regions under stretch or in failing hearts → stabilize unfolded titin and prevent aggregation. HSP90 associates with N2B region (co-chaperone Smyd2 methylates N2A → HSP90 binding).
• Proteases: Calpain-1 and MMP-2 pre-digest titin at proximal I-band/Z-disc or M-band regions. Increased under ischaemia or anthracycline treatment → excess titin breakdown.
• UPS: E3 ligases MuRF1/MuRF2 bind A-band/M-band titin and preferentially ubiquitinate A-band proteins. UPS activity is reduced in HF → accumulation of ubiquitinated but non-degraded titin.
• Autophagy: TK domain binds Nbr1/SQSTM1(p62) complex → autophagy receptor for ubiquitinated titin. Autophagosome activity decreases with age. Role in HF is incompletely understood.

4. TTNtv Cardiomyopathy — Pathomechanisms

• TTNtv is the most common genetic cause of DCM: 15–25% of DCM cohorts. Also the most common genetic predisposition in restrictive, non-compaction, peripartum cardiomyopathy, and acquired CMP (alcohol, anthracyclines).
• Location-dependent risk: Truncations in the A-band carry the highest odds ratio for DCM (prevalence in DCM 10.74% vs. control 0.24%; OR 49.8). I-band central truncations in low-PSI exons (low percentage spliced-in) confer near-population-level risk (OR 1.5).
• Three converging pathomechanisms (Fomin et al., Sci Transl Med 2021):
  1. Titin haploinsufficiency: TTNtv-DCM hearts contain less wt-titin protein than non-TTNtv DCM or donor hearts → fewer sarcomeres per unit area → chronic contractile deficiency.
  2. Truncated protein toxicity (poison-peptide/dominant-negative): tr-titin proteins are stably expressed in adult human TTNtv-DCM hearts (up to 50% of total titin pool). Unlike wt-titin, tr-titin is not incorporated into sarcomeres — instead sequestered in cytoplasmic aggregates. Higher tr-titin content correlates with younger age at transplantation → disease-relevant.
  3. PQC failure: UPS becomes overwhelmed/downregulated (including reduced MuRF1 expression) with advancing disease. Aggregate formation promotes autophagy, but UPS is the primary failure point.
• Nonsense-mediated decay of TTNtv mRNA is not a prominent feature in adult patient hearts.
• Therapeutic proof-of-concept in hiPSC-CMs:
  • UPS inhibition → increased wt-titin → improved contractility (despite raised tr-titin)
  • CRISPR/Cas9 correction of TTNtv → normalized wt-titin, absent tr-titin, full contractility recovery
• Phenotypic diversity in TTNtv carriers reflects the interplay of lifelong haploinsufficiency, late-onset tr-titin accumulation and PQC failure, and additional environmental/genetic second hits.

5. Therapeutic Strategies (Pre-Clinical / Translational)

• Isoform switching: RBM20 inhibition to increase N2BA:N2B → lower stiffness → potential HFpEF benefit, but RBM20 also regulates Ca²⁺-handling proteins (off-target risk).
• PTM targeting: cGMP-PKG boosting (sildenafil, BNP, sGC stimulators); NAD⁺/NAM for acetylation; neuregulin-1 for phosphorylation. All pre-clinically promising; clinical trials largely negative.
• PQC modulation: Chaperone induction (sHSPs), autophagy activators (spermidine), MMP-2/calpain inhibitors (doxorubicin cardioprotection), UPS modulators (MuRF1-interfering small molecules).
• Gene correction: CRISPR/Cas9 in hiPSC-CMs fully restores contractility; pathway to clinical application requires in vivo delivery solutions.

Limitations of the Document

• Invited review: no primary data; selection and interpretation bias from the Linke lab's own research emphasis.
• Much of the PTM and PQC mechanistic data comes from animal models (mouse, rat, dog) and hiPSC-CMs — translation to adult human disease is not established.
• Isoform switch data in human HF has conflicting results across studies; methodological heterogeneity (gel electrophoresis, disease stage, chamber) not fully resolved.
• Therapeutic interventions targeting titin specifically remain entirely pre-clinical or failed in major clinical trials; no currently approved titin-targeted therapy exists.
• Titin's gigantic size prevents full recombinant expression, limiting mechanistic studies to small fragments.

Key Concepts Mentioned

• concepts/Titin-Isoform-Switch — N2B vs N2BA ratio as a stiffness regulator in health and HF
• concepts/Titin-PTMs — Acetylation, oxidation, phosphorylation of titin spring
• concepts/HFpEF — Titin stiffness as a pathophysiological mechanism; cGMP-PKG targeting
• concepts/iPSC-Derived-Cardiomyocytes — hiPSC-CM disease modelling for TTNtv-DCM

Key Entities Mentioned

• entities/TTN — Primary subject; molecular biology, isoforms, PTMs, TTNtv pathomechanisms
• entities/DCM — TTNtv as most common genetic DCM cause; new triple pathomechanism model
• entities/Heart-Failure — HFpEF and HFrEF titin stiffness changes

Wiki Pages Updated

• wiki/sources/TTN-CVResearch-2022.md — created
• wiki/sourceindex.md — updated
• wiki/wikiindex.md — updated
• wiki/entities/TTN.md — molecular biology section added
• wiki/entities/DCM.md — TTNtv pathomechanisms section added
• wiki/concepts/HFpEF.md — titin stiffness mechanisms added
• wiki/concepts/Titin-PTMs.md — created (new)
• wiki/concepts/Titin-Isoform-Switch.md — created (new)